Citadel Advisors
XTNT icon

Citadel Advisors’s Xtant Medical Holdings XTNT Stock Holding History

Citadel Advisors’s Portfolio XTNT Stock Details XTNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$89.8K Sell
161,011
-126,787
-44% -$78K ﹤0.01% 12101
2025
Q4 		$226K Buy
287,798
+207,721
+259% +$151K ﹤0.01% 10776
2025
Q3 		$52K Buy
80,077
+13,369
+20% +$8.43K ﹤0.01% 12185
2025
Q2 		$49.3K Sell
66,708
-27,407
-29% -$15.6K ﹤0.01% 11772
2025
Q1 		$44.2K Buy
+94,115
New +$49.6K ﹤0.01% 12433
2024
Q4 		– Sell
-79,356
Closed -$53.6K – 15510
2024
Q3 		$53.6K Buy
79,356
+3,909
+5% +$2.58K ﹤0.01% 11827
2024
Q2 		$47.5K Buy
75,447
+9,994
+15% +$7.97K ﹤0.01% 11819
2024
Q1 		$76.6K Buy
65,453
+5,587
+9% +$6.13K ﹤0.01% 11709
2023
Q4 		$67.6K Buy
59,866
+28,105
+88% +$33K ﹤0.01% 11425
2023
Q3 		$34.9K Buy
31,761
+4,652
+17% +$4.99K ﹤0.01% 12151
2023
Q2 		$25.2K Buy
27,109
+4,606
+20% +$3.07K ﹤0.01% 12534
2023
Q1 		$14.3K Sell
22,503
-21,155
-48% -$15.4K ﹤0.01% 13317
2022
Q4 		$28.8K Buy
+43,658
New +$28.5K ﹤0.01% 12790
2021
Q3 		– Sell
-36,531
Closed -$60K – 14786
2021
Q2 		$60K Sell
36,531
-55,442
-60% -$98.6K ﹤0.01% 13253
2021
Q1 		$217K Buy
91,973
+24,917
+37% +$53.2K ﹤0.01% 11539
2020
Q4 		$80K Buy
+67,056
New +$86.3K ﹤0.01% 10345
2018
Q1 		– Sell
-1,138
Closed -$8K – 8866
2017
Q4 		$8K Buy
+1,138
New +$8.97K ﹤0.01% 7901
2017
Q1 		– Sell
-3,913
Closed -$26K – 8131
2016
Q4 		$26K Buy
3,913
+2,390
+157% +$20.6K ﹤0.01% 7027
2016
Q3 		$21K Buy
+1,523
New +$28K ﹤0.01% 7032
2014
Q2 		– Sell
-420
Closed -$42K – 8357
2014
Q1 		$42K Buy
420
+266
+173% +$21K ﹤0.01% 6891
2013
Q4 		$9K Buy
+154
New +$9.84K ﹤0.01% 6735

Other funds holding XTNT

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.04B AUM 17.78% 1-Year Est. Return
HIM
Hillsdale Investment Management Toronto, Ontario, Canada $3.68B AUM 62.12% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Citadel Advisors's XTNT Position: Q1 2026 in Review

Citadel Advisors reduced its Xtant Medical Holdings (XTNT) stake by 44% in Q1 2026, selling an estimated $78K and leaving 161,011 shares worth $89.8K. The position accounts for ﹤0.01% of the portfolio, ranked #12101.

Citadel Advisors first reported a position in XTNT in Q4 2013 and has held it in 21 quarters since. The position peaked at $226K in Q4 2025. 34 funds tracked by Wall St. Rank hold XTNT as of Q1 2026.

  • Citadel Advisors held 161,011 shares of Xtant Medical Holdings worth $89.8K as of Q1 2026.
  • Citadel Advisors sold 126,787 Xtant Medical Holdings shares in Q1 2026, an estimated $78K.
  • Xtant Medical Holdings made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12101 holding.
  • Citadel Advisors first reported a position in Xtant Medical Holdings in Q4 2013 and has held it in 21 quarters since.
  • Citadel Advisors's Xtant Medical Holdings position peaked at $226K in Q4 2025.
  • 34 funds tracked by Wall St. Rank held Xtant Medical Holdings as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.